Success of Direct-Acting, Antiviral-Based Therapy for Chronic Hepatitis C Is Not Affected by Type 2 Diabetes
Article Information
vol. 38 no. 1 40-46
Published By
Print ISSN
Online ISSN
History
- Published in print January 17, 2020.
- Published online ahead of print May 31, 2019.
Article Versions
- Previous version (May 31, 2019 - 08:03).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2019 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.
Author Information
- Blake A. Niccum1,
- Jonathan G. Stine2,
- Javelle A. Wynter3,
- Virginia Kelly3,
- Stephen H. Caldwell3 and
- Neeral L. Shah3
- 1Department of Internal Medicine, Massachusetts General Hospital, Boston, MA
- 2Division of Gastroenterology and Hepatology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA
- 3Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, VA
- Corresponding author: Neeral L. Shah, ns3zt{at}virginia.edu
Statistics from Altmetric.com
Article usage
In this Issue
January 2020, 38(1)
Success of Direct-Acting, Antiviral-Based Therapy for Chronic Hepatitis C Is Not Affected by Type 2 Diabetes
